A5067973844- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Glycosylation and Glycoproteins Research
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Ubiquitin and proteasome pathways
- Microtubule and mitosis dynamics
- Lung Cancer Research Studies
- Metastasis and carcinoma case studies
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- 3D Printing in Biomedical Research
- Renal and related cancers
- Single-cell and spatial transcriptomics
- Genetics, Bioinformatics, and Biomedical Research
Cornell University
2022-2025
Weill Cornell Medicine
2022-2025
New York Hospital Queens
2024-2025
Presbyterian Hospital
2024-2025
NewYork–Presbyterian Hospital
2024-2025
Fondazione IRCCS Istituto Nazionale dei Tumori
2015-2024
Northwestern University
2020-2023
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2021-2023
Midwestern University
2020-2022
ORCID
2021
Abstract Circulating tumor cell (CTC) clusters mediate metastasis at a higher efficiency and are associated with lower overall survival in breast cancer compared to single cells. Combining single-cell RNA sequencing protein analyses, here we report the profiles of primary cells lung metastases triple-negative (TNBC). ICAM1 expression increases by 200-fold three TNBC patient-derived xenografts (PDXs). Depletion abrogates colonization inhibiting homotypic cell-tumor cluster formation. Machine...
Abstract Large numbers of cells are generally required for quantitative global proteome profiling due to surface adsorption losses associated with sample processing. Such bulk measurement obscures important cell-to-cell variability (cell heterogeneity) and makes proteomic impossible rare cell populations (e.g., circulating tumor (CTCs)). Here we report a surfactant-assisted one-pot preparation coupled mass spectrometry (MS) method termed SOP-MS label-free single-cell proteomics. capitalizes...
Abstract Bone metastases can disseminate to secondary sites and promote breast cancer progression creating additional clinical challenges. The mechanisms contributing metastasis are barely understood. Here, we evaluate the prediction power of Her2-expressing (Her2E) circulating tumor cells (CTCs) after analyzing over 13,000 CTCs from a cohort 137 metastatic (MBC) patients with initial HR+/Her2- status employ preclinical models bone (BM) validate role Her2E in multi-organ metastases. While...
Importance Black patients with metastatic breast cancer (mBC) have higher mortality rates than White despite advances in treatment. Objectives To examine whether different genomic profiles compared and there are inequities targeted treatment use between these groups. Design, Setting, Participants This retrospective, population-based cohort study assessed adult mBC who underwent profiling at academic institutions the US January 1, 2015, December 31, 2023. Data analysis was performed July 2023...
Abstract Most circulating tumor cells (CTC) are detected as single cells, whereas a small proportion of CTCs in multicellular clusters with stemness properties possess 20- to 100-times higher metastatic propensity than the cells. Here we report that CTC dynamics both singles and response therapies predict overall survival for breast cancer. Chemotherapy-evasive relatively quiescent specific loss ST6GAL1-catalyzed α2,6-sialylation glycoproteins. Dynamic hyposialylation or deficiency ST6GAL1...
Abstract: Liquid biopsy has emerged as a crucial tool in managing breast cancer (BC) patients, offering minimally invasive approach to detect circulating tumor biomarkers. Until recently, the majority of studies BC focused on evaluating single liquid analyte, primarily DNA and cells (CTCs). Despite proven prognostic predictive value CTCs, their low abundance when detected using enrichment methods, especially early stages, poses significant challenge. It is becoming evident that combining...
Circulating tumor cells (CTCs) are promising biomarkers for prognosis, therapeutic response prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal cell carcinoma (RCC) shows low expression of markers hindering CTC-enrichment approaches exploiting surface proteins. In 21 blood samples serially collected from 10 patients with metastatic RCC entering the TARIBO trial, we overcame this limitation using marker-independent Parsortix™ approach coupled positive...
The clinical relevance of circulating tumor cell clusters (CTC-clusters) in breast cancer (BC) has been mostly studied using the CellSearch®, a marker-dependent method detecting only epithelial-enriched clusters. However, due to epithelial-to-mesenchymal transition, resorting marker-independent approaches can improve CTC-cluster detection. Blood samples collected from healthy donors and spiked-in with mammospheres, or BC patients, were processed for detection 3 technologies: CellSieve™...
As the continuation beyond progression (BP) of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is becoming increasingly attractive for treatment patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC), definition resistance factors crucial. The aim study was to investigate impact CDK 4/6i BP and explore potential genomic stratification factors.
<div>Abstract<p>Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort 137 patients with metastatic initial HR<sup>+</sup>/HER2<sup>−</sup> status use preclinical models bone (BM)...
<p>Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary 2 therapeutic effect Tras-ALN on metastasis spread bone models HR+ breast via uCT, live ex vivo bioluminescence profiling organs. 3 shows increased expression in MSC 3D coculture anti-ER treatment conditions. 4 immune-independent blocking progression. 5 that...
The immune ecosystem is central to maintaining effective defensive responses. However, how cells in the periphery blood interact with circulating tumor (CTCs) - seeds of metastasis remains largely understudied. Here, our analysis specimens (N=1,529) from patients advanced breast cancer revealed that over 75% CTC-positive contained heterotypic CTC clusters CD45 + white (WBCs). Detection CTC-WBC correlates subtypes (triple negative and luminal B), racial groups (Black), decreased survival...
Abstract Circulating tumor cells (CTCs) are cancer that detach from tumors, enter the blood and seed distant sites. CTCs spread as single cells, or cluster aggregates, can be heterogenous with differing biological phenotypes, i.e. epithelial, mesenchymal, progenitor, & stem cell. Three clinically relevant CTC subtypes often described in patients (pts) 1) normal epithelial traits (strong filamentous cytokeratin (CK+ CD45-/CD14-), 2) Epithelial-mesenchymal (EMTs), downregulated upregulated...
Abstract The dogma of single tumor cell-mediated metastasis has been challenged by the discovery multicellular circulating cells (CTCs) clusters which are 20-50 times more likely to produce viable than CTCs. However, molecular mechanisms underlying CTC and interactions with immune largely unknown. Combining integrated proteomic ranking, targeted analyses, functional determination, we identified transmembrane protein Plexin-B2 (PLXNB2) as one top hits whose expression in human primary tumors...
Abstract Studies have described the efficacy of immunotherapies (IMT) utilizing programmed death 1 receptor and its ligand (PD-L1) for treating solid tumors. However, many patients (pts) fail to respond IMT, underscoring need better predictive biomarkers improved pt identification stratification. Poor IMT responses are often attributed dynamic nature PD-L1 which may change after chemotherapy or radiation is quantified by static immunostaining. Recently, studies upregulation in giant...
Purpose To compare circulating tumor cell (CTC) detection rates in patients with early (M 0 ) and metastatic + breast cancer using 2 positive-selection methods or size-based unbiased enrichment. Methods Blood collected at baseline different times during treatment from M undergoing neoadjuvant therapy women starting a new line of was processed parallel AdnaTest EMT-1/ EMT-2/Stem CellSelect/Detect kits ScreenCell Cyto devices. CTC positivity defined according to the suggested cutoffs...